Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares for the month of November 2025. The filing details a share repurchase executed on November 6, 2025, acting through BNP Paribas SA as the broker. The transaction is part of an existing buyback programme established under a non-discretionary agreement announced on September 30, 2025.
Key Financial Metrics and Transaction Details
The filing focuses exclusively on capital structure changes via share repurchases. No revenue, profit, cash flow, or debt metrics are provided in this specific document.
- Shares Purchased (Nov 6, 2025): 170,000 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,769.50p; highest price paid was 1,786.00p.
- Volume-Weighted Average Price (VWAP): 1,778.72p.
- Trading Venues: Purchases were executed across BATE (16,890 shares), CHIX (51,494 shares), and XLON (101,616 shares).
- Cumulative Programme Activity: Since September 30, 2025, the Company has purchased 7,989,000 ordinary shares.
- Treasury Holdings: Following this purchase, the Company holds 255,453,844 ordinary shares in treasury.
- Shares in Issue: 4,059,969,755 ordinary shares (excluding Treasury shares).
- Voting Rights: Treasury shares represent 6.29% of the total voting rights.
Material Changes
The primary material change reported is the reduction of shares in issue and the increase in treasury stock. The filing does not provide comparative financial data (e.g., year-over-year revenue or earnings) to assess operational changes. The share count in issue decreased by 170,000 shares as a result of the November 6 transaction.
Guidance, Outlook, and Risks
The filing contains no specific financial guidance or operational outlook. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks and uncertainties. These risks are referenced as being described in the "Risk Factors" section of GSK's Annual Report on Form 20-F for 2024 and its Q3 Results for 2025. No unusual items or contingencies are disclosed in this specific report.
Investor Verification Checklist
- Verify the total remaining authorization under the buyback programme announced on September 30, 2025.
- Confirm the impact of the 6.29% treasury holding on earnings per share (EPS) calculations.
- Review the referenced 2024 Form 20-F and 2025 Q3 Results for detailed risk factors and financial performance context not included in this filing.
- Monitor future 6-K filings for updates on the cumulative number of shares repurchased under the non-discretionary agreement.